Gossamer Bio reports FY2021 net loss of $234M; cash $325M; pipeline milestones set for 2022

Gossamer Bio, Inc.

Net loss for Q4 2021 was $56.3M ($0.74/share); FY2021 net loss $234M ($3.13/share).
Cash, cash equivalents and marketable securities totaled $325.2M at year-end 2021; expected to fund into H2 2023.
GB004 Phase 2 SHIFT-UC topline data (mild-to-moderate UC) expected Q2 2022; treat-through week 36 data in Q4 2022.
Seralutinib (GB002) Phase 2 TORREY PAH study topline data expected H2 2022, subject to COVID-19 developments.
GB5121 IND active; global Phase 1b/2 trial for primary CNS lymphoma expected to initiate in H1 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.